CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 5, 2018--
Therapeutics, Inc. (NASDAQ:MCRB) today announced that management
will host a conference call and live audio webcast on November 8, 2018
at 8:30 a.m. ET to discuss third quarter 2018 results and provide a
general business update.
To access the conference call, please dial 844-277-9450 (domestic) or
336-525-7139 (international) and reference the conference ID number
9877087. To join the live webcast, please visit the “Investors and
Media” section of the Seres website at www.serestherapeutics.com.
A webcast replay will be available on the Seres website beginning
approximately two hours after the event and will be archived for
approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. (NASDAQ:MCRB) is a leading microbiome
therapeutics platform company developing a novel class of biological
drugs that are designed to treat disease by restoring the function of a
dysbiotic microbiome, where the state of bacterial diversity and
function is imbalanced. Seres’ lead program, SER-109, has obtained
Breakthrough Therapy and Orphan Drug designations from the U.S. Food and
Drug Administration and is in Phase 3 development for multiply recurrent C.
difficile infection. SER-287 has successfully completed a Phase 1b
study in patients with mild-to-moderate ulcerative colitis. Seres is
developing SER-262, the first ever synthetic microbiome therapeutic
candidate, in a Phase 1b study in patients with primary C. difficile
infection. Seres is also developing SER-401 to augment the efficacy of
immuno-oncology treatment. For more information, please visit www.serestherapeutics.com.
Follow us on Twitter @SeresTx.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181105005273/en/
Source: Seres Therapeutics, Inc.
IR or PR:
Tanzi, Ph.D., 617-203-3467
Vice President Investor Relations and